Gynecologic Oncology
Research activity is centered on platinum-resistant advanced high-grade epithelial ovarian cancer, with additional interest in primary peritoneal cancer and fallopian tube cancer.
- Advanced epithelial ovarian cancer
- Primary peritoneal cancer
- Fallopian tube cancer
The clinical focus is on malignancies that remain difficult to treat after standard platinum-based therapy.
Targeted Cancer Therapy
The sponsor’s trial activity includes mirvetuximab soravtansine, reflecting interest in therapies directed at tumors with high folate receptor-alpha expression.
- Folate receptor-alpha–positive disease
- Targeted antibody-drug conjugate therapy
- Biomarker-defined solid tumors
This area links treatment development to receptor expression patterns in ovarian and related gynecologic cancers.
Recurrent and Resistant Disease
Clinical interest extends to cancers with platinum resistance, where treatment options are limited and disease control is more challenging.
- Platinum-resistant cancer
- Relapsed gynecologic malignancies
- Post-chemotherapy disease
The trial portfolio is aligned with therapeutic strategies for patients whose disease has progressed after prior systemic therapy.
Oncology Comparative Treatment Evaluation
The funded study examines outcomes against investigator’s choice of chemotherapy, placing emphasis on comparative treatment performance in advanced cancer care.
- Comparative chemotherapy approaches
- Progression-free survival
- Advanced solid tumor outcomes
This research area is focused on assessing clinical benefit in women with advanced gynecologic cancers.
